-
公开(公告)号：US20240376144A9
公开(公告)日：2024-11-14
申请号：US18171798
申请日：2023-02-21
Applicant: Sage Therapeutics, Inc.
Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
-
公开(公告)号：US20230322849A1
公开(公告)日：2023-10-12
申请号：US18334209
申请日：2023-06-13
Applicant: SAGE THERAPEUTICS, INC.
CPC classification number: C07J43/003 , C07J41/0044 , C07J41/0094
Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(0)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
-
3.发明公开公开(公告)号：US20240051987A1
公开(公告)日：2024-02-15
申请号：US18171798
申请日：2023-02-21
Applicant: Sage Therapeutics, Inc.
CPC classification number: C07J43/003 , C07J7/002
Abstract: Provided herein is a compound of Formula (I)
or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.-
公开(公告)号：US20190248831A1
公开(公告)日：2019-08-15
申请号：US16316853
申请日：2017-07-11
Applicant: SAGE THERAPEUTICS, INC.
Inventor： Albert Jean ROBICHAUD , Gabriel MARTINEZ BOTELLA , Boyd L. HARRISON , Francesco G. SALITURO , Andrew GRIFFIN , Maria Jesus BLANCO-PILLADO
CPC classification number: C07J41/0005 , A61P5/00 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/28 , C07J1/0029 , C07J1/0081 , C07J1/0085 , C07J7/002 , C07J9/00 , C07J17/00 , C07J41/0011 , C07J41/005 , C07J41/0066 , C07J41/0094 , C07J43/003
Abstract: Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
-
Patent Agency Ranking
公开(公告)号：US20230322847A1
公开(公告)日：2023-10-12
申请号：US18334124
申请日：2023-06-13
Applicant: SAGE THERAPEUTICS, INC.
CPC classification number: C07J43/003 , C07J41/0044 , C07J41/0094
Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b) N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
-
公开(公告)号：US20210363175A1
公开(公告)日：2021-11-25
申请号：US17286524
申请日：2019-10-21
Applicant: SAGE THERAPEUTICS, INC.
Inventor： Francesco G. SALITURO , Maria Jesus BLANCO-PILLADO , Marshall Lee MORNINGSTAR , Boyd L. HARRISON
Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3, R6a, R6b, R2a, R2b, R4a, R4b, R7a, R7b, R11, R12a, R12b, R16, R21a, R21b, and R21c are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
-
公开(公告)号：US20230322848A1
公开(公告)日：2023-10-12
申请号：US18334189
申请日：2023-06-13
Applicant: SAGE THERAPEUTICS, INC.
CPC classification number: C07J43/003 , C07J41/0044 , C07J41/0094
Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
-
公开(公告)号：US20220372067A1
公开(公告)日：2022-11-24
申请号：US17416367
申请日：2019-12-20
Applicant: SAGE THERAPEUTICS, INC.
Inventor： Maria Jesus BLANCO-PILLADO , Francesco G. SALITURO
IPC: C07J43/00
Abstract: Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted heteroaryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
-
公开(公告)号：US20210340172A1
公开(公告)日：2021-11-04
申请号：US17284206
申请日：2019-10-11
Applicant: SAGE THERAPEUTICS, INC.
Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.017 seconds)
